VMD Stock Forecast 2025-2026
Distance to VMD Price Targets
VMD Price Momentum
10 Quality Stocks Worth Considering Now
Researching Viemed (VMD) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on VMD and similar high-potential opportunities.
Latest VMD Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, VMD has a bullish consensus with a median price target of $12.50 (ranging from $11.00 to $15.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $7.20, the median forecast implies a 73.6% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VMD Analyst Ratings
VMD Price Target Range
Latest VMD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VMD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 3, 2021 | RBC Capital | Frank Morgan | Outperform | Maintains | $9.00 |
| Mar 5, 2021 | RBC Capital | Outperform | Initiates | $0.00 |
Viemed Healthcare Inc. (VMD) Competitors
The following stocks are similar to Viemed based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Viemed Healthcare Inc. (VMD) Financial Data
Viemed Healthcare Inc. has a market capitalization of $288.51M with a P/E ratio of 26.1x. The company generates $224.26M in trailing twelve-month revenue with a 5.0% profit margin.
Revenue growth is +19.6% quarter-over-quarter, while maintaining an operating margin of +8.8% and return on equity of +9.2%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Viemed Healthcare Inc. (VMD) Business Model
About Viemed Healthcare Inc.
Provides in-home respiratory care services.
The company operates by delivering personalized healthcare solutions, primarily for patients with chronic respiratory conditions like COPD. It generates revenue through comprehensive services such as disease management, ventilator therapy, and patient monitoring, ensuring ongoing care that extends beyond traditional healthcare facilities.
Viemed is positioned to meet the increasing demand for home-based chronic care, especially among the aging population. With a focus on utilizing advanced technology and skilled therapists, it aims to enhance patient outcomes and improve quality of life, making it a significant player in the home healthcare and respiratory therapy sectors.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
1,179
CEO
Mr. Casey Hoyt
Country
United States
IPO Year
N/A
Website
www.viemed.comViemed Healthcare Inc. (VMD) Latest News & Analysis
Viemed Healthcare, Inc. (NASDAQ: VMD) will hold its Q4 2024 Earnings Conference Call on March 11, 2025, at 11:00 AM ET, featuring key executives and analysts.
The earnings call provides insights into Viemed Healthcare's financial performance and future outlook, influencing investor sentiment and potential stock price movements.
Viemed Healthcare, Inc. (NASDAQ: VMD) reported its financial results for Q4 and the full year 2024, and announced guidance for 2025 on March 10, 2025.
Viemed Healthcare's financial results and future guidance reveal its performance and growth potential, influencing investor sentiment and stock valuation in the healthcare sector.
Viemed Healthcare, Inc. (NASDAQ: VMD) will hold its Q3 2024 results conference call on November 7, 2024, at 12:00 PM ET, featuring key executives and analysts.
Viemed Healthcare's Q3 2024 results call provides insights into financial performance and future guidance, impacting stock valuation and investor sentiment.
Viemed Healthcare, Inc. (NASDAQ: VMD) announced its financial results for Q3 and the first nine months of 2024, highlighting its position as a leader in respiratory care and home medical equipment services.
Viemed's financial results could impact its stock performance, reflecting its operational health and growth potential in the competitive healthcare market.
Viemed Healthcare upgraded to 'Buy' based on strong Q2 earnings of $55M, positive growth trends, and bullish technical indicators suggesting potential share price increase.
Upgrading Viemed Healthcare to 'Buy' highlights potential for share price growth driven by strong earnings, positive technical indicators, and robust trends in key business segments.
Viemed Healthcare, Inc. (NASDAQ: VMD) will hold its Q2 2024 earnings conference call on August 8, 2024, at 11:00 AM ET, featuring COO Todd Zehnder and CEO Casey Hoyt.
The earnings call provides insights into Viemed's financial performance and strategy, crucial for assessing future growth and investment potential. Market reactions may follow based on the call's outcomes.
Frequently Asked Questions About VMD Stock
What is Viemed Healthcare Inc.'s (VMD) stock forecast for 2025?
Based on our analysis of 2 Wall Street analysts, Viemed Healthcare Inc. (VMD) has a median price target of $12.50. The highest price target is $15.00 and the lowest is $11.00.
Is VMD stock a good investment in 2025?
According to current analyst ratings, VMD has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $7.20. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for VMD stock?
Wall Street analysts predict VMD stock could reach $12.50 in the next 12 months. This represents a 73.6% increase from the current price of $7.20. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Viemed Healthcare Inc.'s business model?
The company operates by delivering personalized healthcare solutions, primarily for patients with chronic respiratory conditions like COPD. It generates revenue through comprehensive services such as disease management, ventilator therapy, and patient monitoring, ensuring ongoing care that extends beyond traditional healthcare facilities.
What is the highest forecasted price for VMD Viemed Healthcare Inc.?
The highest price target for VMD is $15.00 from at , which represents a 108.3% increase from the current price of $7.20.
What is the lowest forecasted price for VMD Viemed Healthcare Inc.?
The lowest price target for VMD is $11.00 from at , which represents a 52.8% increase from the current price of $7.20.
What is the overall VMD consensus from analysts for Viemed Healthcare Inc.?
The overall analyst consensus for VMD is bullish. Out of 2 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $12.50.
How accurate are VMD stock price projections?
Stock price projections, including those for Viemed Healthcare Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
